Do you need a license to sell peptides in Texas?

There is no single "peptide license" issued in Texas, and that is precisely why the question trips up new resellers. What you need depends on which of three separate lanes your business is operating in: ordinary business formation and tax permitting that applies to selling anything at all; drug or prescription-device distribution licensing, which attaches to a product's regulatory classification rather than to the word "peptide"; and the research-use-only (RUO) supply lane, where compounds move as laboratory materials and are never offered as therapeutics. Sorting your inventory into the correct lane is the whole exercise — and that determination belongs to your attorney and the relevant state agency, not to a supplier. This article is informational only and is not legal advice.

Three different questions hiding inside one

When a med spa owner, clinic operator, telehealth founder, or reseller asks about licensing, they are usually asking three questions at once without realizing it.

The first is simply about being a business. Selling anything commercially generally means a registered entity, a sales and use tax permit where taxable sales occur, and whatever local permitting your city or county applies to a commercial address. None of that is peptide-specific. Your CPA and the state's business-registration and tax agencies handle it, and it is the least interesting part of the answer — but it is also the part people skip when they buy inventory before they have a legal entity to buy it under.

The second question is the one with real teeth: is what you are selling regulated as a drug, a prescription device, or a compounded preparation? Most states operate licensing frameworks for wholesale distribution of prescription drugs and devices, and there are federal statutes governing drug distribution and supply-chain custody as well. Those frameworks turn on how a product is classified and how it is presented — not on the chemical family it belongs to. Ask counsel which classification applies to each SKU you intend to stock, because the answer can differ from one item to the next.

The third question is about the RUO lane. Research-use-only compounds are sold as laboratory materials for in-vitro and non-clinical research, are not FDA-approved drugs, and are not offered for human or veterinary use. Whether your business can operate cleanly in that lane depends far less on a certificate you hang on the wall and far more on how you label, describe, market, and document what you sell.

Classification is driven by presentation, not chemistry

Here is the mechanism most new buyers miss. Regulators generally evaluate what a product is by looking at how it is presented — the label, the website copy, the sales conversation, the packaging, the customer it is aimed at. Two vials of identical material can sit in different regulatory categories because one is described as a laboratory reference material and the other carries language about symptoms, dosing, or outcomes.

That has a practical consequence for a wholesale buyer: your compliance exposure is created mostly by your own copywriting and your own sales process. A supplier can give you RUO labeling and batch documentation. Only your business decides whether your product pages, intake scripts, social posts, and email sequences stay inside that framing. If your marketing describes administration, protocols, or results in people, you have arguably repositioned the product — and the licensing question changes with it.

The durable rule to take to counsel is this: ask them how intended use is assessed in your jurisdiction, what evidence a regulator would look at, and which of your marketing assets would be reviewed. Then have them review those assets before launch rather than after a complaint.

The questions to put in front of your attorney and the state board

Do not ask a lawyer "can I sell peptides?" You will get a hedge, because the question is unanswerable as written. Ask the narrower questions below, one SKU category at a time.

The pattern is that almost nothing here is answered by a single form. It is answered by classification first, then by the licensing framework that follows from that classification. Anyone who tells you the whole thing collapses into one permit is guessing — including any supplier who assures you no licensing question exists.

Documentation is the part you actually control

Whatever lane your counsel places you in, the records requirement is similar in shape: you should be able to show, for any unit in your inventory, where it came from, what batch it belongs to, and what that batch tested at. That is not an abstract nicety. It is the file you hand to a regulator, an insurer, a landlord, a payment processor, or a business customer who asks a hard question.

A workable batch file generally contains the certificate of analysis tied to the specific lot number on the vial, the identity and purity method used, the supplier's invoice and shipping record, and your own receiving log showing date and condition on arrival. If your supplier issues COAs that are not linked to lot numbers — or issues one "representative" COA reused across batches — you cannot build that file, no matter how good your internal process is. The supplier's documentation practice becomes your documentation ceiling.

This is why supplier diligence and licensing diligence are the same project. Sorting out your legal lane is wasted effort if the goods arriving at your door cannot be traced back to a tested batch.

What to verify before you place a first wholesale order

Industry practice varies more than most first-time buyers expect, and some of the variation is a warning sign rather than a preference.

Start with testing. Ask which analytical methods are run, whether purity is confirmed by HPLC, and whether testing is per batch or per product line. Per-product-line testing tells you what one lot looked like once. Per-batch testing tells you what is in the box you are opening. Ask what else is screened beyond purity — identity confirmation and contamination panels matter to a documentation file, and a supplier that runs a broader panel can say so plainly.

Then check COA access. A certificate of analysis you can pull up yourself, without asking a rep, is a materially different product than a COA that arrives as an emailed PDF on request — or worse, one sold as a paid add-on. Charging for lab documentation, or providing test results that cannot be traced to a named lab and a lot number, should end the evaluation.

Then check pricing transparency. Programs that hide tier structure behind a call inevitably price by negotiation, which means you cannot model catalog economics before you commit. Margins in this category vary widely with volume, category, and how you position your own brand, so what you need is not a promised number but a published structure you can run your own math against.

Finally, check fulfillment and labeling. Where does stock ship from, what is the realistic lead time, and does every unit arrive with research-use-only labeling intact? Relabeling on your end is not a fix; it is a new problem.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around the documentation a business buyer actually has to produce.

Compounds are tested to 99%+ HPLC purity, with 7-panel batch testing rather than a single representative result carried forward across lots. Certificates of analysis are publicly verifiable — a prospective partner can check the lab results before applying, not after signing, and can point a business customer to the same records without brokering a request through a sales rep. COAs are never a paid add-on, because documentation that costs extra is documentation your compliance file will eventually be missing.

Fulfillment is handled from within the United States, generally in five to seven days, which keeps lead times predictable enough to plan reorders around instead of guessing at customs. Everything ships research use only, not for human consumption, and the catalog is organized by research area so a buyer can build a coherent shelf rather than a random assortment — categories such as performance and recovery research and mitochondrial and metabolic pathway research exist for exactly that reason.

The application itself is three steps: submit the wholesale application with your business details, get reviewed and approved, then order at partner pricing. Tier structure is disclosed as part of that process rather than negotiated in the dark. Note also what is not on offer: Real Peptides does not supply prescription weight-management drugs such as semaglutide, tirzepatide, or retatrutide, and any supplier offering them wholesale should raise immediate questions about the framework they believe they are operating in.

What Real Peptides cannot do is tell you your licensing answer. No supplier can. What it can do is make sure the paperwork side of your file is complete when your attorney asks for it.

The path from here

If your entity is formed, your counsel has classified what you intend to stock, and you are ready to evaluate supply on documentation rather than promises, the next step is the Wholesale Partner Program application. Review the published COAs first, confirm the tier structure fits your volume, and apply with your business details — approval is a review of your business, not a formality, and the tier pricing follows it.

For more on program mechanics and the broader legal framework, see the wholesale peptides program overview, the deeper explainer on do you need a license to sell peptides, or apply for a wholesale account when your diligence is done.